Corteva (NYSE:CTVA) Rating Lowered to Strong Sell at Zacks Research

Corteva (NYSE:CTVA) was downgraded by equities research analysts at Zacks Research from a “hold” rating to a “strong sell” rating in a report released on Tuesday, Zacks reports.

CTVA has been the subject of a number of other reports. BMO Capital Markets set a $15.00 price objective on shares of Corteva in a research note on Friday, October 2nd. Oppenheimer set a $17.00 target price on shares of Corteva in a report on Monday. Morgan Stanley reissued an “overweight” rating and set a $18.00 price target on shares of Corteva in a report on Friday, October 2nd. Weiss Ratings downgraded Corteva from a “hold (c+)” rating to a “hold (c)” rating in a research report on Monday, August 3rd. Finally, Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating and issued a $101.00 price objective on shares of Corteva in a research note on Monday, August 3rd. Sixteen research analysts have rated the stock with a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Corteva presently has a consensus rating of “Moderate Buy” and an average price target of $67.45.

Corteva Stock Up 4.7%

CTVA stock opened at $14.56 on Tuesday. Corteva has a twelve month low of $11.74 and a twelve month high of $90.97. The company has a quick ratio of 1.10, a current ratio of 1.52 and a debt-to-equity ratio of 0.07. The stock has a market cap of $9.72 billion, a P/E ratio of 9.64, a PEG ratio of 0.73 and a beta of 0.57. The business’s 50-day moving average price is $74.30 and its 200-day moving average price is $79.19.

Corteva (NYSE:CTVA) last released its earnings results on Thursday, July 30th. The company reported $2.30 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.24 by $0.06. Corteva had a net margin of 5.66% and a return on equity of 10.18%. The company had revenue of $6.38 billion during the quarter, compared to analyst estimates of $6.60 billion. During the same period in the prior year, the firm posted $2.20 EPS. The firm’s quarterly revenue was down 1.2% compared to the same quarter last year. Corteva has set its FY 2026 guidance at 3.600-3.800 EPS. On average, equities research analysts forecast that Corteva will post 2.77 EPS for the current year.

Institutional Investors Weigh In On Corteva

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. BlackRock Inc. bought a new position in shares of Corteva during the 2nd quarter valued at approximately $4,560,180,000. Independent Franchise Partners LLP lifted its position in Corteva by 1.0% in the fourth quarter. Independent Franchise Partners LLP now owns 10,495,388 shares of the company’s stock worth $703,506,000 after buying an additional 107,434 shares during the last quarter. Wellington Management Group LLP lifted its position in Corteva by 941.7% in the second quarter. Wellington Management Group LLP now owns 7,612,704 shares of the company’s stock worth $644,720,000 after buying an additional 6,881,875 shares during the last quarter. Royal Bank of Canada boosted its stake in Corteva by 202.1% during the first quarter. Royal Bank of Canada now owns 7,458,624 shares of the company’s stock worth $624,362,000 after buying an additional 4,989,371 shares during the period. Finally, Jupiter Topco LLC purchased a new position in Corteva during the second quarter worth $544,246,000. 81.54% of the stock is currently owned by hedge funds and other institutional investors.

Key Stories Impacting Corteva

Here are the key news stories impacting Corteva this week:

• Positive Sentiment: JPMorgan upgraded Corteva to Overweight from Neutral and set a $19 price target, implying substantial upside from recent trading levels. The firm views the post-spinoff company as undervalued. JPMorgan Upgrades Corteva to Overweight
• Positive Sentiment: KeyBanc also upgraded Corteva to Overweight following the Vylor spinoff. The second bullish rating reinforces the view that the streamlined Corteva may have better growth and valuation prospects. Corteva upgraded at KeyBanc after spinoff of Vylor
• Positive Sentiment: Options activity has surged. Investors purchased 5,408 call options, compared with typical daily volume of 856. While options flow is not a guarantee of future performance, the increase suggests stronger speculative and institutional interest in further gains.
• Positive Sentiment: Recent coverage has highlighted Corteva’s rally after the spinoff and analyst endorsements, including reports that JPMorgan sees as much as 50% upside at current valuations. Corteva Soars on JPMorgan Upgrade
• Neutral Sentiment: Corteva announced that it will release third-quarter 2026 results after the market close on November 11, followed by a webcast on November 12. The announcement provides a future catalyst but contains no new operating results. Corteva Announces Third-Quarter Earnings Date
• Negative Sentiment: One valuation analysis warned that Corteva could be overvalued after its recent advance. That concern may limit additional upside if future earnings do not support the higher valuation. Corteva Valuation Analysis

About Corteva

Corteva, Inc is an agriculture-focused company that develops and supplies seed, crop protection and digital agriculture products. Its offerings are designed to help farmers improve crop productivity, manage pests and diseases, and support more efficient and sustainable farming practices.

The company’s seed portfolio includes corn, soybean, wheat, sunflower, canola, cotton and other crops, marketed through brands such as Pioneer, Brevant seeds and PhytoGen. Corteva also provides herbicides, insecticides, fungicides, biological products and seed treatments under a range of agricultural brands.

Corteva serves farmers, agricultural retailers and other customers in markets around the world.